Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05501054 · ClinicalTrials.gov registry record · Phase 1

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

A Phase 1 study of Renal Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 1
Development phase
50
Enrollment target
3
Study locations

NCT05501054 is a Phase 1 study of Renal Cell Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (79% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05501054, a Phase 1 study of Renal Cell Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
3
Study locations

Study Summary

To learn if the combination of ciforadenant, ipilimumab, and nivolumab can help to control advanced renal cell carcinoma

Conditions Studied

Renal Cell Carcinoma

Interventions

  • DRUG Nivolumab
  • DRUG Ipilimumab
  • DRUG Ciforadenant

Study Locations (3)

North Carolina

  • Duke Cancer Institute - Durham

Pennsylvania

  • Abramson Cancer Center of the University of Pennsylvania - Philadelphia

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-02-09
Est. Completion 2026-11-01
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05501054

The ClinicalTrials.gov registry entry for NCT05501054 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (79% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.

NCT05501054 reports 3 study locations spanning 3 distinct geographic areas - top geographies include North Carolina, Pennsylvania, Texas.

Frequently Asked Questions

What is clinical trial NCT05501054 about?

NCT05501054 is a clinical study titled "Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.". To learn if the combination of ciforadenant, ipilimumab, and nivolumab can help to control advanced renal cell carcinoma

What is the current status of trial NCT05501054?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2023-02-09. Estimated completion is 2026-11-01.

What conditions does trial NCT05501054 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma.

What interventions are being tested in trial NCT05501054?

The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Ciforadenant (DRUG).

Who is sponsoring clinical trial NCT05501054?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05501054 being conducted?

This trial has 3 study locations across North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.